Agenus Webcast January 2026 | Access To Acceleration: BOT+BAL Global Momentum Entering 2026 Paige Spiranac [BtErebj24xT]

In this recorded saguenens chicoutimi Agenus stakeholder webcast, Garo Armen is joined by leading oncology experts to discuss expanding patient access to next-generation immunotherapy and Agenus momentum entering 2026.

Highlights include a clinical discussion with Robin Jones (Royal Marsden Hospital) on sarcoma and immunotherapy, is discord down the expansion of Frances reimbursed AAC early-access pathway to sarcoma and ovarian cancer, and an update on Agenus strategic collaboration with Zydus Lifesciences, strengthening U.S.-based biologics manufacturing. The webcast also covers growing global physician demand, real-world evidence generation, and pathways to accelerate access for patients with historically hard-to-treat cancers.

Topics: immunotherapy | sarcoma | colorectal cancer | early access programs | French AAC | pete davidson oncology innovation | BOT + BAL